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Abstract
Recent studies have shown acute respiratory distress syndrome (ARDS) to be underdiagnosed and inadequately
treated, as evidenced by underutilization of low-tidal volume ventilation. Despite a proven survival benefit in
patients with severe ARDS, studies have also shown underutilization of prone positioning. Many questions persist as
to the reasons for prone positioning’s unpopularity. Additional studies are required to uncover the causes of this
prone positioning underutilization phenomenon.
Commentary
Recently, an international, multicenter, prospective co-
hort, “The Large Observational Study to Understand the
Global Impact of Severe Acute Respiratory Failure”
(LUNG SAFE) showed acute respiratory distress syn-
drome (ARDS) to be widely unrecognized and inad-
equately treated [1]. Shockingly, the study reported that
clinical recognition of ARDS ranged from 51.3 in mild
to 78.5% in severe ARDS, while less than two-thirds of
ARDS patients received tidal volumes of 8 ml/kg or less,
and only 16.3% with severe ARDS were prone positioned
[1]. After reviewing these results, I initially focused on
the surprisingly poor utilization rate of low-tidal volume
ventilation, an intervention repeatedly proven to have
significant survival benefit and deemed by most to be a
cornerstone in ARDS management [2]. Even more
alarming than this suboptimal use of low-tidal volumes,
however, is the vast underutilization of prone positioning
(PP) for patients with severe ARDS. Just over 3 years
ago the Proning Severe ARDS Patients (PROSEVA)
study investigators showed in their multicenter prospect-
ive randomized control trial of 466 (237 prone vs. 229
supine) patients with severe ARDS (defined as a ratio of
the partial pressure of arterial oxygen to the fraction of
inspired oxygen (Fio2) of less than 150 mmHg) that PP
definitively reduced mortality by 50% (28-day mortality
reduction of 32.8% in supine group to 16.0% in prone
group) [3]. An intervention that reduces mortality by
50%, but is only used in 16.3% of appropriate patients,
begs the question of why. Just imagine the uproar if only
16.4% of patients with CHF with reduced ejection frac-
tion and NYHA III–IV symptoms were prescribed with
aldosterone antagonists, a therapy proven to reduce all-
cause mortality by 30%, or only 16.4% of patients with
moderate or severe COPD were prescribed with long-
acting anticholinergics (i.e., tiotroprium), a universally
prescribed medication that has only shown statistically
significant benefit in reducing exacerbations and not sur-
vival; my guess is that these dismal utilization rates
would be quickly addressed [4, 5]. Since reviewing the
PP literature, I have conversed with colleagues regarding
PP’s unpopularity and underutilization, with the majority
of their responses focusing on PP’s perceived cumber-
someness, burdensome need for additional human re-
sources, and higher rate of adverse events (i.e., pressure
ulcers, accidental extubations, and tracheal tube dis-
placement). Despite this anecdotal majority focus on
PP’s onerousness and higher complication rate, scrutiny
of the literature suggests otherwise [6–10]. Countless
studies, meta-analyses, and reports have continuously
shown notions that PP is difficult to initiate, burden-
some to maintain, and more apt to cause complications
unfounded [11–13]. In fact, Athota et al. reviewed vari-
ous institutional experiences with PP and highlighted its
facility and ease of use, while a recent Cochrane review
found no convincing evidence of harm from universal
application of PP. Thus, many paramount questions re-
garding PP’s unfavorable reputation persist with a couple
being: (1) why is PP so underutilized in the appropriate
setting, and how can we elucidate the causes of this
underutilization phenomenon? (2) Prior to making firm
conclusions about PP’s efficacy, it would be prudent to
conduct multicenter randomized control trials testing
PP’s ability to reduce mortality. Why have these studies
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not been performed? (3) Once the etiologies for PP’s
underuse are determined, what interventions can be im-
plemented to improve the widespread adoption and
utilization rate of PP, and how can we test the efficacy of
these interventions?
Conclusions
PP has enormous potential to save lives in patients with
severe ARDS. Now is the time to focus on ways to ad-
dress and improve the PP underutilization phenomenon
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